Glaxo used ghostwriting program to promote Paxil
British drugmaker GlaxoSmithKline used a sophisticated ghostwriting program to promote its antidepressant Paxil, allowing doctors to take credit for medical journal articles mainly written by company consultants, according to court documents obtained by The Associated Press.
Pharmaceutical giant GlaxoSmithKline PLC is forfeiting $1.4 million in state incentives so that it will have the option of cutting jobs at a facility in Zebulon.